Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.36 |
| ▸ | GSPT1 | P15170 | 5/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 7/20 | 0.33 |
| ▸ | F11 | P03951 | 4/20 | 0.31 |
| ▸ | F9 | P00740 | 2/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | KLK1 | P06870 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26436127 | 0.86 | DDB1 (0.34) | CRBNGSPT1DDB1 | |
| SCHEMBL26436128 | 0.86 | FASN (0.33) | CRBNGSPT1DDB1EGLN2 | |
| SCHEMBL26436126 | 0.86 | RIPK1 (0.34) | CRBNGSPT1DDB1F11EGLN2 | |
| SCHEMBL26133407 | 0.85 | CRBN (0.52) | CRBNGSPT1DDB1 | |
| SCHEMBL26435061 | 0.84 | CRBN (0.35) | CRBNGSPT1DDB1 | |
| SCHEMBL26435942 | 0.82 | GRM4 (0.35) | CRBNGSPT1DDB1F11KLK1 | |
| SCHEMBL26436842 | 0.82 | CRBN (0.33) | CRBNGSPT1DDB1 | |
| SCHEMBL26436043 | 0.81 | CRBN (0.39) | CRBNGSPT1DDB1 | |
| SCHEMBL30407993 | 0.81 | DDB1 (0.40) | CRBNGSPT1DDB1 | |
| SCHEMBL26436839 | 0.81 | DDB1 (0.40) | CRBNGSPT1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |